Prevention of Post-ERCP Pancreatitis by Indomethacin vs Diclofenac

Status Recruiting

Clinical Trial Summary

Post-ERCP pancreatitis (PEP) is the most common complication after ERCP, which was associated with occasional mortality, prolonged hospital days and increased health costs. Some studies investigated the effectiveness of different Nonsteroidal antiinflammatory drugs (NSAIDs) for prevent PEP. However, several high-quality RCTs and meta-analyses consistently demonstrated only100mg rectal indomethacin or diclofenac significantly reduced PEP incidence compared with placebos. Thus, European Society of Gastrointestinal Endoscopy, American Society for Gastrointestinal Endoscopy and Japanese Society of Hepato-Biliary-Pancreatic surgery guidelines recommended rountine administration of 100mg rectal indomethacin or diclofenac in unselected patients who underwent ERCP. Up to date, the mechanisms of NSAIDs in preventing pancreatitis were not fully elucidated. Diclofenac and Indomethacin showed similar inhibitory effects in phospholipase A2 and cyclooxygenase pathways. And the peak concentration of diclofenac and indomethacin both occurs between 30 and 90 min after rectal administration. However, diclofenac may be a stronger inhibitor of other pancreatitis-related imflammatory siginals (e.g. nuclear factor kappa-B) than indomethacin. Recently, several meta-analyses found 100mg rectal diclofenac to be more efficacious than 100mg rectal indomethacin. Despite these data, there is no conclusive evidence to prove that rectal diclofenac could provide incremental benefits over indomethacin from high-quality randomized, controlled trials. Therefore, the investigators conducted a multicenter, double-blind, randomized, controlled clinical trial to evaluate the efficacy of rectal diclofenac versus indomethacin for the prevention of post-ERCP pancreatitis in average-risk patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Endoscopic Retrograde Cholangiopancreatography
Indomethacin
NSAIDs
Pancreatitis
Post-ERCP Acute Pancreatitis

Clinical Trial Details

NCT number	NCT05947461
Study type	Interventional
Source	Air Force Military Medical University, China
Contact
Status	Recruiting
Phase	N/A
Start date	June 1, 2023
Completion date	June 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04546867` - Establishing a Sonographic Based Algorithm to Verify Pancreatic Stent Position Placed to Prevent Post-ERCP Pancreatitis Before Endoscopic Removal	N/A
Terminated	`NCT02241512` - IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis	Phase 2
Completed	`NCT00222092` - Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers	Phase 4
Completed	`NCT05310409` - PAN-PROMISE to Detect Post-ERCP Pancreatitis Symptoms
Not yet recruiting	`NCT06260878` - Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis	Phase 4
Not yet recruiting	`NCT04770857` - Evaluation of Post-ERCP Pain as a Predictor for Post-ERCP Pancreatitis
Completed	`NCT02641561` - Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis	Phase 3
Active, not recruiting	`NCT04145336` - 7 cm vs. 5 cm Pancreatic Stents for the Prevention of Post-ERCP Pancreatitis in High-risk Patients	N/A
Completed	`NCT03629600` - Trial of Aggressive Hydration Versus Rectal Indomethacin for Prevention of Post-ERCP Pancreatitis	Phase 2/Phase 3
Recruiting	`NCT03756116` - Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide	N/A
Recruiting	`NCT05664074` - Rectal Indomethacin vs Intravenous Ketorolac	Phase 4
Completed	`NCT02308891` - A Prospective Trial of Aggressive Hydration Strategy to Reduce Post-ERCP Pancreatitis	N/A
Recruiting	`NCT05336630` - Study of Forceps Cannulation During ERCP	N/A
Recruiting	`NCT05857514` - Randomized Controlled Trial of Rectal Indomethacin Versus Combined Pancreatic Stent Placement and Rectal Indomethacin for Preventing Post-ERCP Pancreatitis	N/A
Recruiting	`NCT05267379` - An European Multi-centre Cohort Study for Unravelling Pharmacokinetic and Genetic Factors Underlying Post-ERCP Pancreatitis
Completed	`NCT03098082` - Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis	N/A
Recruiting	`NCT02839356` - Epinephrine Sprayed on the Papilla for the Prevention of Post-ERCP Pancreatitis	Phase 4
Recruiting	`NCT02830984` - ENBD After Endoscopic Sphincterotomy Plus Large-balloon Dilation for Preventing PEP	N/A
Completed	`NCT01673763` - Post-ERCP Pancreatitis Prevention by Stent Insertion	N/A
Active, not recruiting	`NCT04425993` - Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate for PEP Prevention	N/A